ArborGen H1 revenue up 60.9% and gross margin doubled, but cash burn...

What changed

Revenue from continuing operations rose 60.9% to US$7.4m from US$4.6m, and gross profit more than tripled to US$1.8m, lifting the gross margin from 10.9% to 24.3% – a ~1,345bps step-up. Despite that, the operating loss widened, and PBT deteriorated from -US$0.9m to -US$1.6m (a 77.8% wider loss). Reported NPAT swung from +US$0.1m to -US$1.6m, but the prior period was flattered by a US$0.6m discontinued-operations gain and a US$0.4m tax benefit – so PBT is the cleaner read, and it worsened.

Operating cash flow swung from +US$0.1m to -US$2.4m, and with capex of US$2.4m (including US$1.3m of IP investment), pre-lease free cash flow was -US$4.8m versus -US$1.8m prior. The balance sheet nonetheless strengthened: cash rose to US$8.4m from US$3.9m, gross borrowings fell to US$25.9m from US$33.8m, and net debt dropped to US$17.5m from US$29.9m, implying an external funding event offset the operating burn.

What matters

• Margin expansion is the bullish signal. Gross margin more than doubling on a 60.9% revenue uplift suggests mix toward higher-value product (the release flags Brazil strength and US MCP growth) rather than pure volume leverage. This is the most durable positive.
• Cash conversion deteriorated materially. OCF went from marginally positive to a US$2.4m outflow despite better gross profit, signalling that working-capital build or timing absorbed the margin gains. Inventory at US$42.0m remains the dominant asset and barely moved.
• Leverage improved despite weaker earnings. Net debt fell US$12.4m without the business generating cash – strengthening the balance sheet optically but raising the question of what funded it (equity issuance, asset sale, or refinancing not visible in the extracted excerpts).

Expectations

The release supplies strong seasonality context. HY22 contributed only 9.7% of FY22 revenue (US$4.6m of US$47.6m) and just 5.9% of FY22 NPAT, confirming a heavily second-half-weighted shape tied to planting cycles. A first-half loss is therefore the norm, not the anomaly. Annualising HY23 revenue naively gives US$14.8m – well below FY22's US$47.6m – but that extrapolation is not meaningful given the seasonality.

No quantitative FY23 guidance, forward-work, or order-book data was disclosed in the extracted materials, so the release does not support a reliable FY23 comparison. What it does support: a stronger-margin starting point and directional commentary on Brazil and US MCP. What it does not support: any conclusion about whether the implied US$40m+ second-half revenue step-up is on track.

Quality of result

The mix of signals is split. The gross-margin lift looks real and strategic if Brazil volumes and US MCP continue. Against that, the cash result is poor: a -US$2.4m operating outflow against a US$1.6m reported loss implies non-cash addbacks were more than offset by working-capital absorption, which the extracted materials do not fully bridge. With capex at 32.4% of revenue, the business is investing ahead of the second-half harvest – defensible given the seasonal shape, but it means earnings durability rests on the 2H delivering consistent with prior years.

The balance-sheet improvement is not earnings-driven and therefore does not speak to operating quality; it reflects a US$7.9m reduction in gross borrowings alongside a US$4.5m cash build that the operating result alone cannot explain.

Unresolved

• What funded the US$12.4m net-debt reduction and US$4.5m cash build, given operating cash flow was -US$2.4m and capex absorbed another US$2.4m? The extracted materials do not show an equity raise or asset sale explicitly.
• Why did a tripling of gross profit not translate into any improvement in operating cash flow? Receivables and payables movements are not disclosed in the extraction.
• Is the 1,345bps gross margin step-up sustainable into the seasonally larger second half, or did first-half mix flatter the ratio?
• No dividend, no FY23 guidance, no forward order book, no segment detail, and no NTA disclosure were captured.

This briefing cannot assess FY23 trajectory against management expectations, because no quantitative guidance, forward-work book, or segment-level disclosure was provided in the extracted materials.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.